Marketdash
Back to Stock Market News

Cancer Biotech Erasca Rides the Rumor Mill Rollercoaster

MarketDash Editorial Team
3 days ago
Erasca shares jumped nearly 60% on speculation linking AbbVie to a Revolution Medicines acquisition, only to tumble the next day when the deal chatter fizzled.

Get Abbvie Alerts

Weekly insights + SMS alerts

Erasca Inc. (ERAS) shares had quite the week. On Wednesday, the stock rocketed nearly 60% to $6.12. By Thursday, it had crashed back down to $4.33. Welcome to biotech, where rumor-fueled volatility is just another day at the office.

The wild ride started when reports emerged that AbbVie Inc. (ABBV) was in advanced talks to acquire Revolution Medicines, Inc. (RVMD), a cancer-drug biotech working on treatments for RAS-addicted cancers. The Wall Street Journal reported that Revolution had attracted interest from multiple bidders, citing sources familiar with the discussions.

But the excitement didn't last long. Shortly after the report dropped, AbbVie told Reuters it "is not in discussions with Revolution Medicines." That pretty much deflated the balloon.

So why did Erasca get caught up in all this? The connection comes down to what these companies actually do. Revolution Medicines has a market cap around $19 billion, while Erasca sits at roughly $1.5 billion, but both are developing therapies targeting similar cancer pathways.

Revolution Medicines is a late-stage clinical oncology company building novel targeted therapies for patients with RAS-addicted cancers. Their research pipeline features RAS(ON) inhibitors designed to suppress various oncogenic variants of RAS proteins. Back in September 2025, Revolution shared promising updates from its Daraxonrasib Phase 1 trials, including results in patients with RAS mutant pancreatic cancer.

Erasca operates in the same neighborhood. As a clinical-stage precision oncology company, it's focused on discovering, developing and commercializing therapies for RAS/MAPK pathway-driven cancers. The company is currently running two Phase 1 trials with its lead drug ERAS-0015 in patients with RAS-mutant solid tumors, with initial data expected in 2026.

The Wall Street Journal report noted that acquiring Revolution Medicines would strengthen AbbVie's position in the massive worldwide cancer drug market, valued at over $250 billion. When Big Pharma comes shopping in your therapeutic area, all the smaller players get a speculative bump on the theory that they might be next.

Price Action: Erasca stock was trading 0.87% higher at $5.23, while Revolution Medicines was down 5.65% at $96.91 at publication on Thursday.

Back to Stock Market News

Cancer Biotech Erasca Rides the Rumor Mill Rollercoaster

MarketDash Editorial Team
3 days ago
Erasca shares jumped nearly 60% on speculation linking AbbVie to a Revolution Medicines acquisition, only to tumble the next day when the deal chatter fizzled.

Get Abbvie Alerts

Weekly insights + SMS alerts

Erasca Inc. (ERAS) shares had quite the week. On Wednesday, the stock rocketed nearly 60% to $6.12. By Thursday, it had crashed back down to $4.33. Welcome to biotech, where rumor-fueled volatility is just another day at the office.

The wild ride started when reports emerged that AbbVie Inc. (ABBV) was in advanced talks to acquire Revolution Medicines, Inc. (RVMD), a cancer-drug biotech working on treatments for RAS-addicted cancers. The Wall Street Journal reported that Revolution had attracted interest from multiple bidders, citing sources familiar with the discussions.

But the excitement didn't last long. Shortly after the report dropped, AbbVie told Reuters it "is not in discussions with Revolution Medicines." That pretty much deflated the balloon.

So why did Erasca get caught up in all this? The connection comes down to what these companies actually do. Revolution Medicines has a market cap around $19 billion, while Erasca sits at roughly $1.5 billion, but both are developing therapies targeting similar cancer pathways.

Revolution Medicines is a late-stage clinical oncology company building novel targeted therapies for patients with RAS-addicted cancers. Their research pipeline features RAS(ON) inhibitors designed to suppress various oncogenic variants of RAS proteins. Back in September 2025, Revolution shared promising updates from its Daraxonrasib Phase 1 trials, including results in patients with RAS mutant pancreatic cancer.

Erasca operates in the same neighborhood. As a clinical-stage precision oncology company, it's focused on discovering, developing and commercializing therapies for RAS/MAPK pathway-driven cancers. The company is currently running two Phase 1 trials with its lead drug ERAS-0015 in patients with RAS-mutant solid tumors, with initial data expected in 2026.

The Wall Street Journal report noted that acquiring Revolution Medicines would strengthen AbbVie's position in the massive worldwide cancer drug market, valued at over $250 billion. When Big Pharma comes shopping in your therapeutic area, all the smaller players get a speculative bump on the theory that they might be next.

Price Action: Erasca stock was trading 0.87% higher at $5.23, while Revolution Medicines was down 5.65% at $96.91 at publication on Thursday.